VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial ...
Flutterwave isn’t just building payment pipes anymore; it’s betting on a new kind of money. The company’s latest move to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback